Mandana Khalili, MD

Mandana Khalili, MD

Professor of Medicine, UCSF; Chief of Clinical Hepatology and Director of Clinical and Translational Research in Hepatology, Zuckerberg San Francisco General Hospital (ZSFG)

Cancer Center Program Membership

Cancer Control

[email protected]

Phone: 628-206-4766

Box 0862, UCSF
San Francisco, CA 94143

UCSF Profiles

Research Summary

POSITIONS:
Chief of Clinical Hepatology, San Francisco General Hospital
Director, Clinical and Translational Research in Hepatology, San Francisco General Hospital
Director, Investigator Development Unit, UCSF Research Coordinating Center of the NIMHD/Health Excellence Action Network
Co-Director, UCSF Mentor Training Program
Director, UCSF T32 Hepatology Training Program
Editorial board member, Hepatology Journal

RESEARCH PROGRAM:
Mandana Khalili is a Professor of Medicine in the Department of Medicine. She also serves as the Chief of Clinical Hepatology and Director of Clinical and Transitional Research in Hepatology at the Zuckerberg San Francisco General Hospital (ZSFG). Her research focuses on assessing and addressing health outcomes related to viral hepatitis, metabolic-dysfunction associated steatotic liver disease, alcohol-related liver disease, cirrhosis, and hepatocellular carcinoma including natural history, pathogenesis, metabolic complications, healthcare access and novel treatments. She has a longstanding track record of continuous extramural funding in these areas and has served as PI or co-PI of several NIH-sponsored national and international networks. She currently serves as a PI for the NIDDK-sponsored Liver Cirrhosis Network and also Hepatitis B Research Network assessing the natural history and optimal management of patients with hepatitis B and cirrhosis. Her group previously evaluated mechanisms of insulin resistance and secretion in Latinos with and without hepatitis C infection and is now examining how alcohol affects insulin action and adipose tissue insulin resistance among this at high-risk populations. In collaboration with two VA healthcare systems in the Bay Area, she is evaluating the impact of COVID pandemic and transitions in care delivery on telemedicine satisfaction, quality of life, cirrhosis management, liver cancer screening and substance use among socioeconomically disadvantaged populations in order to implement measures and policies to provide optimal liver care. Her group is also evaluating alcohol treatment in patients with liver disease using a novel stepped care motivational interviewing and addiction medicine treatment in the hepatology setting. Additional studies include examining patient and provider knowledge, attitudes and barriers to viral hepatitis and steatotic liver disease management and implementing novel patient-centered as well as provider interventions such as education through mobile app to enhance patient care and address barriers to care. Her group’s recent efforts in developing an integrated model of shelter-based hepatitis C screening and treatment within large homeless shelters in San Francisco and Minnesota has been successful in scaling up hepatitis C management in persons who inject drugs and homeless residents. She is a member of the Liver Cancer San Francisco Cancer Initiative (SF-CAN), which in partnership with the City and County of San Francisco and other health and community partners, is using interventional strategies to reduce cancer in the city. Dr. Khalili is passionate about mentoring trainees and junior faculty and she has mentored numerous trainee and faculty at all career stages. She is a recipient of a NIH-sponsored K24 award in mentoring junior investigators in liver disease and the co-Director (co-PI) of the T32 Training in Hepatology. She has campus wide leadership roles in mentoring as the Director of UCSF Mentor Training Program. She also currently serves as the Director of Investigator Development Unit of the Research Coordinating Center for addressing Multiple Chronic Diseases sponsored by NIMHD. Her multidisciplinary research program including translational research, natural history and epidemiology, community/participatory research, health services, and clinical trials provides the infrastructure for supporting junior investigators and in transitioning them to independence.

WEBSITES
https://health-excellence-action.org/
http://ctsi.ucsf.edu/about-us/team/programs/career-development-cd
http://accelerate.ucsf.edu/training/mdp-people
http://livercenter.ucsf.edu/members/mkhalili.html
http://ctsi.ucsf.edu/news/about-ctsi/driving-excellence-mentoring-ucsf

Research Funding

  • September 1, 2023 - June 30, 2028 - Learners to LeAders in benign Urology, benign Nephrology, and non-Cancer Hematology , Co-Investigator . Sponsor: NIH/NIDDK, Sponsor Award ID: U2CDK133488
  • August 15, 2023 - May 31, 2028 - Dissecting the Acid Ceramidase Pathway in Hepatic Fibrogenesis , Co-Investigator . Sponsor: NIH/NIDDK, Sponsor Award ID: R01DK134723-01A1
  • July 1, 2022 - June 30, 2027 - NRSA Hepatology Training Grant , Co-PI . Sponsor: NIH/NIDDK, Sponsor Award ID: 5T32DK060414
  • December 22, 2021 - December 31, 2026 - Racial and Ethnic Disparities in Hepatocellular Carcinoma Surveillance Among Patients with Cirrhosis Across Five Safety Net Organizations , UCSF Site Principal Investigator/Co-Investigator . Sponsor: NIH/NIMHD, Sponsor Award ID: R01MD017063
  • September 6, 2021 - August 31, 2026 - Liver Cirrhosis Network: Longitudinal and Clinical Trial Studies , Principal Investigator . Sponsor: NIH, Sponsor Award ID: U01DK130168
  • September 1, 2021 - August 31, 2026 - Research Coordinating Center to Reduce Disparities in Multiple Chronic Diseases (RCC RD-MCD) , Director Investigator Skill Development Unit and Co-Investigator . Sponsor: NIH/NIMHD, Sponsor Award ID: U24MD017250
  • June 1, 2021 - February 28, 2026 - Impact of the COVID-19 pandemic on patient outcomes, telehealth care delivery, and treatment for unhealthy alcohol use in vulnerable patients with advanced liver disease across two healthcare systems , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01AA029312
  • May 1, 2019 - September 30, 2025 - Mentoring Multidisciplinary Patient-Oriented Research in Liver Disease , Principal investigator . Sponsor: NIH/NIAAA, Sponsor Award ID: K24AA022523
  • May 1, 2019 - April 30, 2024 - Mentoring Emerging Scientists for Careers in Substance Use Research , Co-Investigator . Sponsor: NIH/NIDA, Sponsor Award ID: R25DA035163
  • August 1, 2013 - April 30, 2024 - Mentoring Multidisciplinary Patient-Oriented Research in Liver Disease , Principal Investigator . Sponsor: NIH, Sponsor Award ID: K24AA022523
  • September 20, 2019 - August 31, 2023 - Alcohol's impact on immunological and virological profiles in HIV patients , Co-Investigator . Sponsor: NIH/NIAAA, Sponsor Award ID: UH3AA026218
  • August 31, 2015 - November 30, 2022 - Hepatitis B Research Network (HBRN): Natural History and Treatment Studies , Principal Investigator . Sponsor: NIH, Sponsor Award ID: U01DK082944
  • September 23, 2013 - August 31, 2019 - HBV-HIV Coinfection Research Network , Co-Investigator, UCSF Site PI . Sponsor: NIH/NIDDK, Sponsor Award ID: R01 DK 094818
  • April 1, 2008 - February 28, 2015 - Impact of Hepatitis C on Insulin Sensitivity and Insulin Secretion in Latinos , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01DK074673
  • August 15, 2005 - July 31, 2009 - HCV-induced alterations in glucose metabolism , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R03DK071531
  • October 1, 1974 - November 30, 2007 - General Clinical Research Center , Co-Investigator . Sponsor: NIH, Sponsor Award ID: M01RR000083
  • August 1, 2002 - June 30, 2007 - Insulin Resistance in HCV Infection , Principal Investigator . Sponsor: NIH, Sponsor Award ID: K23DK062013

Education

2022 - Diversity, Equity, and Inclusion Champion Training, University of California San Francisco
Mentor Development Program Certificate, 2007 - Research Mentoring, UCSF
M.A.S, 2005 - Masters in Advanced Studies in Clinical and Epidemiologic Research, UCSF
Transplant Hepatology, 1999 - Transplant Hepatology and Post-Doctoral Research, UCSF
Hepatology, 1998 - Hepatology, Ochsner Clinic
Gastroenterology, 1997 - Gastroenterology, McGill University
M.D., 1992 - Medicine, University of Ottawa

Honors & Awards

  • UCSF/ZSFG Department of Medicine Mentoring Award, UCSF, 2024
  • Harold L. Luft Award, Health Disparity Mentoring Award Nomination, UCSF, 2023
  • UCSF Helen Diller Family Comprehensive Cancer Center, Cancer Control Branch, Member, UCSF, 2023
  • Zuckerberg San Francisco DOM Physician COVID-19 Clinical Service Recognition Award, UCSF, 2022
  • Affiliate Faculty, UCSF Philip R. Lee Institute for Health Policy Studies, 2022
  • Visiting Professor, Department of Scientific Research, Peking Union Medical College, Beijing, China, 2019
  • Certificate of Appreciation-Mentor Training Program, Peking Union Medical College, Beijing, China, 2018
  • Harold L. Luft Award, Health Disparity Mentoring Award Nomination, UCSF, 2017
  • ZSFG Distinction in Medical Education Award Nomination, UCSF, 2016
  • Academic Senate Distinction in Mentoring Award Nomination, UCSF, 2015
  • Mid-Career Investigator Award in Patient Oriented Research, NIH, 2014
  • Academic Senate Distinction in Mentoring Award Nomination, UCSF, 2013
  • UCSF University Community Partnerships Council Service Learning Award, UCSF, 2009
  • Longitudinal Clinical Experience Appreciation Certificate, UCSF, 2008
  • Recognizing Discovery and Innovation in 2001: Milestones in Hepatitis C, Hepatitis Innovation Award, Schering Oncology, 2001
  • American Digestive Health Foundation, Martin Brotman Training and Transition Award, Gastroenterology Research Group, 2000
  • Natural Sciences and Engineering Research Council Award, Canada, 1988
  • J.W. McConnell Entrance Award, McGill University, 1986

Selected Publications

  1. Wong RJ, Jones PD, Niu B, Pinheiro P, Thamer M, Kshirsagar O, Zhang Y, Fass R, Therapondos G, Singal AG, Khalili M. Hepatocellular Carcinoma Surveillance in Cirrhosis Patients at U.S. Safety-Net Health Systems. Clin Transl Gastroenterol. 2025 Jun 25.  View on PubMed
  2. Rubin JB, Loeb R., Monto A., Wong RJ., ·Cheung R., Batki SL, Ostacher MJ, Shen H, Hoggatt KJ, Satre D, Khalili M. COVID-19 pandemic-related disruptions in routine cirrhosis care and associated clinical outcomes among San Francisco Bay Area Veterans. Gastro Hep Advances. 2025.  View on PubMed
  3. Tsuchiyose E, Salimi A, Magee C, Khalili M. Culturally tailored steatotic liver disease management: Latino and Asian community partner perspectives and recommendations. Hepatol Commun. 2025 Jul 01; 9(7).  View on PubMed
  4. Kim R, Patel S, Shui AM, Magee C, Chen JY, Tana M, Khalili M.. Clinical Outcomes Following a Patient-Centered Educational Intervention on Steatotic Liver Disease: A Comparison of Vulnerable Patients with and without Diabetes. Gastro Hep Advances. 2025.  View on PubMed
  5. Traum D, Wong DK, Lau DT, Sterling RK, Terrault NA, Khalili M, Wahed AS, Lee WM, Block TM, Lok ASF, Chang KM, Hepatitis B Research Network (HBRN). HBV-specific T-cell function is nonenhanced by tenofovir-induced decline in HBV viremia or HBsAg titer in chronic hepatitis B. Hepatol Commun. 2025 Jun 01; 9(6).  View on PubMed
  6. Thomas MD, Khalili M, Vittinghoff E, Cournos F, Olfson M, Dahiya P, et al.. Hepatitis C virus-related liver cancer among Medicaid recipients with schizophrenia, 2002–2012. Journal of Medicine, Surgery, and Public Health. 2025;6:100199. 2025.  View on PubMed
  7. Peluso MJ, Sandel DA, Deitchman AN, Kim SJ, Dalhuisen T, Tummala HP, Tibúrcio R, Zemelko L, Borgo GM, Singh SS, Schwartz K, Deswal M, Williams MC, Hoh R, Shimoda M, Narpala S, Serebryannyy L, Khalili M, Vendrame E, SenGupta D, Whitmore LS, Tisoncik-Go J, Gale M, Koup RA, Mullins JI, Felber BK, Pavlakis GN, Reeves JD, Petropoulos CJ, Glidden DV, Spitzer MH, Gama L, Caskey M, Nussenzweig MC, Chew KW, Henrich TJ, Yukl SA, Cohn LB, Deeks SG, Rutishauser RL. Combination immunotherapy induces post-intervention control of HIV. Res Sq. 2025 Mar 19.  View on PubMed
  8. Patel S, Bull L, Salimi K, Shui AM, Siao K, Yang B, Maher JJ, Khalili M. Exploring the impact of graded alcohol use on atherogenic lipid profiles among Latinos with underlying chronic liver disease. Alcohol Clin Exp Res (Hoboken). 2025 Apr; 49(4):792-803.  View on PubMed
  9. Patel S, Khalili M, Singal AG, Pinheiro PS, Jones PD, Kim RG, Kode V, Thiemann A, Zhang W, Cheung R, Wong RJ. Significant Disparities in Hepatocellular Carcinoma Outcomes by Race/Ethnicity and Sociodemographic Factors. Cancer Epidemiol Biomarkers Prev. 2025 Feb 06; 34(2):355-365.  View on PubMed
  10. Luk JW, Ha NB, Shui AM, Snyder HR, Batki SL, Ostacher MJ, Monto A, Wong RJ, Cheung R, Parekh P, Hua W, Tompkins DA, Fakadej T, Haight CG, Liao M, Khalili M, Satre DD. Demographic and clinical characteristics associated with utilization of alcohol use disorder treatment in a multicenter study of patients with alcohol-associated cirrhosis. Alcohol Clin Exp Res (Hoboken). 2025 Jan; 49(1):244-255.  View on PubMed
  11. Patel S, Partida D, Magee C, Garza Romero FE, Chen JY, Tana M, Khalili M. Steatotic Liver Disease Education Enhances Knowledge and Confidence to Adhere to Provider Recommendations in Diverse and Vulnerable Populations. Gastro Hep Adv. 2025; 4(3):100589.  View on PubMed
  12. Satre DD, Dasarathy D, Batki SL, Ostacher MJ, Snyder HR, Hua W, Parekh P, Shui AM, Cheung R, Monto A, Wong RJ, Chen JY, Liao M, Tana M, Chen PH, Haight CG, Fakadej T, Khalili M. Factors Associated With Motivation to Reduce Alcohol Use Among Patients With Chronic Liver Disease. Aliment Pharmacol Ther. 2025 Feb; 61(3):481-490.  View on PubMed
  13. Murnane PM, Afshar M, Chamie G, Cook RL, Ferguson T, Haque LY, Jacobson KR, Justice AC, Kim TW, Khalili M, Krupitsky E, McGinnis KA, Molina P, Muyindike WR, Myers B, Richards VL, So-Armah K, Stewart S, Sulkowski MS, Tien PC, Hahn JA. Using Phosphatidylethanol as an Adjunct to Self-Reported Alcohol Use Improves Identification of Liver Fibrosis Risk. Am J Gastroenterol. 2024 Oct 31.  View on PubMed
  14. Klepper A, Asaki J, Kung AF, Vazquez SE, Bodansky A, Mitchell A, Mann SA, Zorn K, Avila-Vargas I, Kari S, Tekeste M, Castro J, Lee B, Duarte M, Khalili M, Yang M, Wolters P, Price J, Perito E, Feng S, Maher JJ, Lai JC, Weiler-Normann C, Lohse AW, DeRisi J, Tana M. Novel autoantibody targets identified in patients with autoimmune hepatitis (AIH) by PhIP-Seq reveals pathogenic insights. medRxiv. 2024 Oct 29.  View on PubMed
  15. Flanary J, King EA, Baimaji F, Strauss AT, Welch N, Bellar A, Sherman CB, Hameed B, Khalili M, Dasarathy S, Cameron AM, Chen PH. Recipients of Early Liver Transplants for Alcohol-Related Liver Disease May Reside in Areas With Lower Social Vulnerability. Gastro Hep Adv. 2025; 4(1):100542.  View on PubMed
  16. Erlandson KM, Geng LN, Selvaggi CA, Thaweethai T, Chen P, Erdmann NB, Goldman JD, Henrich TJ, Hornig M, Karlson EW, Katz SD, Kim C, Cribbs SK, Laiyemo AO, Letts R, Lin JY, Marathe J, Parthasarathy S, Patterson TF, Taylor BD, Duffy ER, Haack M, Julg B, Maranga G, Hernandez C, Singer NG, Han J, Pemu P, Brim H, Ashktorab H, Charney AW, Wisnivesky J, Lin JJ, Chu HY, Go M, Singh U, Levitan EB, Goepfert PA, Nikolich JŽ, Hsu H, Peluso MJ, Kelly JD, Okumura MJ, Flaherman VJ, Quigley JG, Krishnan JA, Scholand MB, Hess R, Metz TD, Costantine MM, Rouse DJ, Taylor BS, Goldberg MP, Marshall GD, Wood J, Warren D, Horwitz L, Foulkes AS, McComsey GA, RECOVER-Adult Cohort. Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort. Ann Intern Med. 2024 Sep; 177(9):1209-1221.  View on PubMed
  17. Tapper EB, Goldberg D, Parikh ND, Terrault NA, Welch N, Sharpton S, Hameed B, Khalili M, Stolz A, Verna EC, Brown RS, Sanyal AJ, VanWagner L, Ladner DP, Moylan CA, Diehl AM, Jones PD, Loomba R, Dasarathy S, Simonetto DA, Shah VH, Bajaj JS, LCN Study Group. The Liver Cirrhosis Network Cohort Study: Cirrhosis Definition, Study Population, and Endpoints. Am J Gastroenterol. 2025 Mar 01; 120(3):570-575.  View on PubMed
  18. Ghany MG, King WC, Hinerman AS, Lok ASF, Lisker-Melman M, Chung RT, Terrault N, Janssen HLA, Khalili M, Lee WM, Lau DTY, Cloherty GA, Sterling RK. Reply: The exact predictive value of HBcrAg and HBV RNA in serological status and disease activity in CHB. Hepatology. 2024 Nov 01; 80(5):E82-E84.  View on PubMed
  19. Wong RJ, Jones PD, Niu B, Therapondos G, Thamer M, Kshirsagar O, Zhang Y, Pinheiro P, Kyalwazi B, Fass R, Khalili M, Singal AG. Clinician-Level Knowledge and Barriers to Hepatocellular Carcinoma Surveillance. JAMA Netw Open. 2024 05 01; 7(5):e2411076.  View on PubMed
  20. Luk JW, Satre DD, Cheung R, Wong RJ, Monto A, Chen JY, Batki SL, Ostacher MJ, Snyder HR, Shui AM, Liao M, Haight CG, Khalili M. Problematic alcohol use and its impact on liver disease quality of life in a multicenter study of patients with cirrhosis. Hepatol Commun. 2024 02 01; 8(2).  View on PubMed

Go to UCSF Profiles, powered by CTSI